Nordea Investment Management AB raised its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA – Get Rating) by 227.9% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 234,476 shares of the company’s stock after buying an additional 162,970 shares during the quarter. Nordea Investment Management AB’s holdings in Teva Pharmaceutical Industries were worth $2,161,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Signaturefd LLC grew its position in Teva Pharmaceutical Industries by 85.7% in the 4th quarter. Signaturefd LLC now owns 2,962 shares of the company’s stock worth $27,000 after purchasing an additional 1,367 shares during the last quarter. Ronald Blue Trust Inc. grew its holdings in shares of Teva Pharmaceutical Industries by 1,232.2% during the 4th quarter. Ronald Blue Trust Inc. now owns 3,677 shares of the company’s stock worth $30,000 after purchasing an additional 3,401 shares in the last quarter. Toronto Dominion Bank acquired a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter worth approximately $31,000. Edmond DE Rothschild Holding S.A. grew its holdings in shares of Teva Pharmaceutical Industries by 213.8% during the 3rd quarter. Edmond DE Rothschild Holding S.A. now owns 6,678 shares of the company’s stock worth $54,000 after purchasing an additional 4,550 shares in the last quarter. Finally, U.S. Capital Wealth Advisors LLC acquired a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter worth approximately $54,000. Institutional investors and hedge funds own 50.39% of the company’s stock.
Insider Transactions at Teva Pharmaceutical Industries
In other news, EVP Sven Dethlefs sold 59,655 shares of the business’s stock in a transaction that occurred on Tuesday, February 28th. The stock was sold at an average price of $9.89, for a total value of $589,987.95. Following the transaction, the executive vice president now directly owns 165,381 shares of the company’s stock, valued at approximately $1,635,618.09. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Teva Pharmaceutical Industries news, VP David Matthew Stark sold 63,383 shares of the company’s stock in a transaction on Tuesday, February 28th. The stock was sold at an average price of $9.89, for a total transaction of $626,857.87. Following the transaction, the vice president now owns 2,974 shares of the company’s stock, valued at approximately $29,412.86. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Sven Dethlefs sold 59,655 shares of the company’s stock in a transaction on Tuesday, February 28th. The stock was sold at an average price of $9.89, for a total value of $589,987.95. Following the transaction, the executive vice president now directly owns 165,381 shares in the company, valued at approximately $1,635,618.09. The disclosure for this sale can be found here. Insiders have sold 158,884 shares of company stock valued at $1,572,797 in the last three months. 0.82% of the stock is owned by corporate insiders.
Teva Pharmaceutical Industries Stock Performance
Teva Pharmaceutical Industries (NYSE:TEVA – Get Rating) last announced its earnings results on Wednesday, February 8th. The company reported $0.68 EPS for the quarter, topping the consensus estimate of $0.64 by $0.04. The business had revenue of $3.88 billion for the quarter, compared to the consensus estimate of $3.90 billion. Teva Pharmaceutical Industries had a positive return on equity of 28.06% and a negative net margin of 15.76%. On average, equities analysts forecast that Teva Pharmaceutical Industries Limited will post 2.28 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
TEVA has been the topic of several recent research reports. StockNews.com initiated coverage on Teva Pharmaceutical Industries in a report on Thursday, March 16th. They set a “buy” rating on the stock. Barclays lifted their target price on shares of Teva Pharmaceutical Industries from $13.00 to $14.00 and gave the company an “overweight” rating in a research report on Thursday, February 9th. Finally, Jefferies Financial Group lowered shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating and lifted their target price for the company from $10.00 to $12.00 in a research report on Thursday, January 19th. Three equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, Teva Pharmaceutical Industries has a consensus rating of “Hold” and a consensus price target of $10.75.
Teva Pharmaceutical Industries Profile
Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.
Featured Articles
- Get a free copy of the StockNews.com research report on Teva Pharmaceutical Industries (TEVA)
- An Updraft Is Brewing For DraftKings
- PepsiCo Hits “Sweet Spot” For APAC Growth, Macros Agree
- High-Risk Mullen Automotive Continues To Build Momentum
- 3 Recession-Proof Stocks With Nice Dividends
- Oracle Stock Climbs For Third Month, Still In Buy Range
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.
